Planned Parenthood loses bid to stop regulation of medical abortion
This article originally appeared in this issue of the WSR: 2012-10-03

Objecting to a 2004 Ohio law that requires Planned Parenthood to abide by FDA regulations when dispensing the abortion drug RU-486, Planned Parenthood of Southwest Ohio filed suit to block the law. This week, the Sixth Circuit Court of Appeals rejected the abortion giant’s challenge.

Americans United for Life reports:

The FDA approved the abortion drug regimen RU-486 (under the brand name Mifeprex) for use only through 49 days of pregnancy. The regimen actually involves two different drugs: oral administration of mifepristone on day one, followed by an oral administration of misoprostol on day 3 (together known as the Mifeprex regimen). The FDA approved the drug regimen under a special code section that allows the FDA to restrict the use of the drugs.

Not only did the FDA approve the drug just through 49 days gestation, but the FDA specifically outlined that women are to take each dose in a clinic or physician’s office, with the second dose in the regimen to be taken orally. However, abortion providers—including Planned Parenthood—purposely flout these restrictions, providing the drugs past 49 days and instructing women to take the second dose at home vaginally or buccally (not orally).

But providing the Mifeprex regimen outside the restrictions approved by the FDA is dangerous.

In 2011, the FDA reported that 14 women had died after using the Mifeprex regimen, and eight of these women had died from a bacterial infection.

Planned Parenthood’s lawsuit is just one more example of its attitude that it is above the law and can do as it pleases as it continues its almost unbridled daily killing spree. Despite the fact that the so-called champion of women knew that its use of the abortion drugs outside the FDA recommendations were resulting in the death of women, it chose to challenge the law prohibiting that use, illustrating once more that Planned Parenthood is waging a war against women.